Bioequivalence of two esomeprazole magnesium enteric-coated formulations in healthy Chinese subjects

Table 3 Bioequivalence analysis of esomeprazole (fasting arm)–primary endpoint pharmacokinetics parameters (bioequivalence analysis set)

	Average bioequivalence					Reference-scaled average bioequivalence				Intra-subject variability (%)
Parameters	n	GLSmean T	GLSmean R	Ratio (%) (T vs R)	90%CI (%)	S2wr	Swr	Point estimate (0.8, 1.25)	Criteria bound (≤ 0)	CVwt	CVwr
Cmax (ng/mL)	32	1591.275	1527.891	104.15	(98.20, 110.46)	0.0427	0.2067	1.0415	-0.0193	15.04	20.89
AUC0-t (h*ng/mL)	32	3786.532	3597.451	105.26	(99.80, 111.01)	0.0484	0.2199	1.0526	-0.0228	18.39	22.26
AUC0-inf (h*ng/mL)	32	3830.746	3635.508	105.37	(99.97, 111.06)	0.0473	0.2175	1.0537	-0.0222	18.31	22.01

AUC: Area under the curve.